Ferring Pharmaceuticals’ Collaboration with Hybio Pharmaceutical Co.

Sidley Austin advised Ferring Pharmaceuticals on the deal.

Ferring Pharmaceuticals (China) Co., Ltd. announced its strategic collaboration with Hybio Pharmaceutical Co., Ltd. where the Marketing Authorization of Cetrotide (cetroelix acetate for injection) in Mainland China will be transferred to Ferring Pharmaceuticals; and Hybio Pharmaceutical will act as the contract manufacturing organization of Ferring Pharmaceuticals.

Headquartered in St. Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group as well as a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.

The Sidley team was led by senior counsel Chen Yang (Picture) and counsel Jing Lu.

Involved fees earner: Jing Lu – Sidley Austin LLP; Chen Yang – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Ferring Pharmaceuticals Inc.;

Author: Sonia Carcano